Scholarlink

Aims <p>To investigate whether the prognostic impact of lipoxin A4 (LXA4) is affected by diabetes mellitus (DM) and insulin resistance (IR), as indicated by the triglyceride-glucose index (TyG).</p> Materials and methods <p>A total of 1569 consecutive patients with acute myocardial infarction (AMI) were prospectively recruited between March 2017 and January 2020. Plasma LXA4 levels were determined using enzyme-linked immunosorbent assay. Patients were stratified into four groups according to DM and TyG (high vs. low). The primary outcome was major adverse cardiovascular event (MACE), a composite of all-cause death, recurrent MI, ischemic stroke, and ischemia-driven revascularizations.</p> Results <p>High levels of LXA4 (≥ 5.637 ng/mL) were associated lower risk of MACE (hazard ratio [HR]: 0.42, 95% confidence interval [CI]: 0.28–0.65, <i>P</i> &lt; 0.001) in non-DM patients with low TyG (&lt; 5.461) after multiple adjustments, which was not observed in patients with DM or high TyG (<i>P</i> <sub>interaction</sub> = 0.044). The risk reduction of MACE was mainly driven by fewer recurrent MI (HR, 0.21; 95% CI: 0.08–0.59; <i>P</i> = 0.003) and ischemia-driven revascularizations (HR: 0.45, 95% CI :0.25–0.80, <i>P</i> = 0.007).</p> Conclusion <p>In patients with AMI, ischemic risk reduction associated with high LXA4 levels is attenuated by DM and IR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic impacts of lipoxin A4 in relation to diabetes and insulin resistance in patients with acute myocardial infarction: a prospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Runzhen Chen,
  • Weida Liu,
  • Xiaoxiao Zhao,
  • Nan Li,
  • Chen Liu,
  • Peng Zhou,
  • Yi Chen,
  • Shaodi Yan,
  • Jiannan Li,
  • Li Song,
  • Hongbing Yan,
  • Hanjun Zhao

摘要

Aims

To investigate whether the prognostic impact of lipoxin A4 (LXA4) is affected by diabetes mellitus (DM) and insulin resistance (IR), as indicated by the triglyceride-glucose index (TyG).

Materials and methods

A total of 1569 consecutive patients with acute myocardial infarction (AMI) were prospectively recruited between March 2017 and January 2020. Plasma LXA4 levels were determined using enzyme-linked immunosorbent assay. Patients were stratified into four groups according to DM and TyG (high vs. low). The primary outcome was major adverse cardiovascular event (MACE), a composite of all-cause death, recurrent MI, ischemic stroke, and ischemia-driven revascularizations.

Results

High levels of LXA4 (≥ 5.637 ng/mL) were associated lower risk of MACE (hazard ratio [HR]: 0.42, 95% confidence interval [CI]: 0.28–0.65, P < 0.001) in non-DM patients with low TyG (< 5.461) after multiple adjustments, which was not observed in patients with DM or high TyG (P interaction = 0.044). The risk reduction of MACE was mainly driven by fewer recurrent MI (HR, 0.21; 95% CI: 0.08–0.59; P = 0.003) and ischemia-driven revascularizations (HR: 0.45, 95% CI :0.25–0.80, P = 0.007).

Conclusion

In patients with AMI, ischemic risk reduction associated with high LXA4 levels is attenuated by DM and IR.